Hospitals face permanent pay cuts if they don't buy American PPE

What it does

This bill creates a 9-year pilot program requiring large hospitals to purchase at least 40% of their personal protective equipment and medical consumables from domestic manufacturers, with financial penalties (2–8% reimbursement cuts) for non-compliance. It funds hospital reimbursements through tariffs on imported medical supplies (phased to 300% ad valorem over 5 years) and offers tax credits to domestic PPE manufacturers and investors in PPE production facilities.

Why we flagged it

The bill's core mechanism is a mandate on hospitals (40% domestic purchasing) paired with financial penalties for non-compliance, funded by tariffs on imported medical supplies. The tariff revenue is then used to reimburse hospitals for domestic purchases, creating a closed-loop subsidy system. Tax credits for domestic manufacturers are a secondary incentive layer.

What the text implies

• Tariff phase-in (10% → 100% over 5 years) will progressively increase hospital procurement costs for imported PPE, potentially raising prices for patients and straining hospital budgets before domestic capacity fully scales.
• The 40% domestic purchasing requirement applies only to hospitals that received above-average Medicare payments in the prior 5 years—smaller, lower-revenue hospitals are excluded, creating a two-tier system and potentially disadvantaging rural or safety-net hospitals.
• Reimbursement cuts (2–8%) persist indefinitely after the 9-year program ends, creating permanent financial pressure on hospitals that fail to meet targets even after the pilot concludes.
• Attestation forms (manufacturer self-certification under penalty of perjury) are the sole verification mechanism for 'domestic product' status; no third-party audit or supply-chain transparency requirement is specified, creating enforcement risk.
• Tax credits for PPE manufacturers (per-unit production credits up to $250 per ventilator, 20% investment credit) are uncapped and available through 2035, potentially creating significant federal revenue loss if domestic production scales rapidly.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Hospitals face mandatory domestic purchasing requirements backed by reimbursement penalties, which may increase their costs and potentially raise patient care expenses or reduce hospital margins; however, the bill aims to rebuild domestic PPE manufacturing capacity and reduce supply-chain vulnerability. Tariffs on imported medical supplies will likely increase prices for hospitals and consumers in the short term, but the stated goal is to incentivize domestic production. The net citizen benefit

Who stands to gain

• Domestic PPE manufacturers (production tax credits + tariff-protected market access)
• Investors in PPE manufacturing facilities (20% investment tax credit)
• Large hospitals meeting domestic purchasing targets (reimbursement for domestic PPE purchases)

Named in the bill

Secretary of Health and Human Services, Secretary of the Treasury, Eligible hospitals (above-average Medicare payment recipients), Domestic PPE manufacturers, Federal Hospital Insurance Trust Fund, Internal Revenue Service, Harmonized Tariff Schedule of the United States

Where it stands

• Sep 24, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Sep 24, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.